<?xml version='1.0' encoding='utf-8'?>
<document id="30597998"><sentence text="Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan."><entity charOffset="45-54" id="DDI-PubMed.30597998.s1.e0" text="Memantine" /></sentence><sentence text="Several basic pharmacokinetic and pharmacological studies were conducted as part of a group of studies to clarify the drug-drug interaction (DDI) between memantine (MEM), a drug used to treat Alzheimer's disease, and yokukansan (YKS), a traditional Japanese Kampo medicine used to treat behavioral and psychological symptoms of dementia"><entity charOffset="154-163" id="DDI-PubMed.30597998.s2.e0" text="memantine" /></sentence><sentence text=" The pharmacokinetic studies showed that there were no statistically significant differences in MEM concentrations in the plasma, brain, and urine between mice treated with MEM alone and with MEM plus YKS" /><sentence text=" Regarding candidate active ingredients of YKS, there were also no statistically significant differences in concentrations of geissoschizine methyl ether in the plasma and brain, urine, glycyrrhetinic acid in the plasma, and isoliquiritigenin in the urine, in mice treated with YKS alone or with MEM plus YKS"><entity charOffset="126-153" id="DDI-PubMed.30597998.s4.e0" text="geissoschizine methyl ether" /><entity charOffset="186-205" id="DDI-PubMed.30597998.s4.e1" text="glycyrrhetinic acid" /><entity charOffset="225-242" id="DDI-PubMed.30597998.s4.e2" text="isoliquiritigenin" /><pair ddi="false" e1="DDI-PubMed.30597998.s4.e0" e2="DDI-PubMed.30597998.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30597998.s4.e0" e2="DDI-PubMed.30597998.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30597998.s4.e0" e2="DDI-PubMed.30597998.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30597998.s4.e1" e2="DDI-PubMed.30597998.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30597998.s4.e1" e2="DDI-PubMed.30597998.s4.e2" /></sentence><sentence text=" The pharmacological studies showed that isoliquiritigenin, which has an N-methyl-d-aspartic acid (NMDA) receptor antagonistic effect, did not affect the inhibitory effect of MEM on NMDA-induced intracellular Ca2+ influx in primary cultured rat cortical neurons"><entity charOffset="41-58" id="DDI-PubMed.30597998.s5.e0" text="isoliquiritigenin" /><entity charOffset="73-97" id="DDI-PubMed.30597998.s5.e1" text="N-methyl-d-aspartic acid" /><entity charOffset="99-103" id="DDI-PubMed.30597998.s5.e2" text="NMDA" /><entity charOffset="209-213" id="DDI-PubMed.30597998.s5.e3" text="Ca2+" /><entity charOffset="182-185" id="DDI-PubMed.30597998.s5.e4" text="NMDA" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e0" e2="DDI-PubMed.30597998.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e0" e2="DDI-PubMed.30597998.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e0" e2="DDI-PubMed.30597998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e0" e2="DDI-PubMed.30597998.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e0" e2="DDI-PubMed.30597998.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e1" e2="DDI-PubMed.30597998.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e1" e2="DDI-PubMed.30597998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e1" e2="DDI-PubMed.30597998.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e1" e2="DDI-PubMed.30597998.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e2" e2="DDI-PubMed.30597998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e2" e2="DDI-PubMed.30597998.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e2" e2="DDI-PubMed.30597998.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e4" e2="DDI-PubMed.30597998.s5.e4" /><pair ddi="false" e1="DDI-PubMed.30597998.s5.e4" e2="DDI-PubMed.30597998.s5.e3" /></sentence><sentence text=" Moreover, YKS did not affect either the ameliorative effects of MEM on NMDA-induced learning and memory impairment, or the MEM-induced decrease in locomotor activities in mice"><entity charOffset="72-75" id="DDI-PubMed.30597998.s6.e0" text="NMDA" /></sentence><sentence text=" These results suggest that there is probably no pharmacokinetic or pharmacological interaction between MEM and YKS in mice, but more detailed studies are needed in the future" /><sentence text=" Our findings provide important information for future studies, to clarify the DDI more regarding the efficacy and safety of combined use of these drugs in a clinical situation" /><sentence text="" /></document>